Kymera Therapeutics Inc. (NASDAQ: KYMR) stock fell -1.70% on Friday to $19.05 against a previous-day closing price of $19.38. With 1.52 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.39 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $19.53 whereas the lowest price it dropped to was $18.67. The 52-week range on KYMR shows that it touched its highest point at $39.85 and its lowest point at $18.42 during that stretch. It currently has a 1-year price target of $55.31. Beta for the stock currently stands at 1.51.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of KYMR was up-trending over the past week, with a rise of 0.58%, but this was down by -1.09% over a month. Three-month performance dropped to -31.15% while six-month performance fell -38.73%. The stock lost -31.50% in the past year, while it has lost -23.68% so far this year. A look at the trailing 12-month EPS for KYMR yields -2.76 with Next year EPS estimates of -3.32. For the next quarter, that number is -0.72. This implies an EPS growth rate of -37.40% for this year and -27.70% for next year.
Float and Shares Shorts:
At present, 58.33 million KYMR shares are outstanding with a float of 54.62 million shares on hand for trading. On Aug 30, 2023, short shares totaled 7.16 million, which was 12.93% higher than short shares on Jul 30, 2023. In addition to KYMR as the firm’s Kymera Therapeutics, Inc., KLMR serves as its K.L.M.(KONINKLIJKE LUCHTVAART M.
Institutional Ownership:
Through their ownership of 105.97% of KYMR’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 51.58% of KYMR, in contrast to 42.51% held by mutual funds. Shares owned by individuals account for 19.65%. As the largest shareholder in KYMR with 8.92% of the stake, T. Rowe Price Associates, Inc. holds 4,940,700 shares worth 4,940,700. A second-largest stockholder of KYMR, Wellington Management Co. LLP, holds 4,822,683 shares, controlling over 8.70% of the firm’s shares. BVF Partners LP is the third largest shareholder in KYMR, holding 4,739,004 shares or 8.55% stake. With a 4.83% stake in KYMR, the T Rowe Price New Horizons Fund is the largest stakeholder. A total of 2,678,307 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 3.34% of KYMR stock, is the second-largest Mutual Fund holder. It holds 1,851,140 shares valued at 35.32 million. Vanguard Health Care Fund holds 2.60% of the stake in KYMR, owning 1,442,019 shares worth 27.51 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, KYMR reported revenue of $11.51M and operating income of -$40.81M. The EBITDA in the recently reported quarter was -$39.51M and diluted EPS was -$0.78.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for KYMR since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With KYMR analysts setting a high price target of $93.00 and a low target of $31.00, the average target price over the next 12 months is $55.31. Based on these targets, KYMR could surge 388.19% to reach the target high and rise by 62.73% to reach the target low. Reaching the average price target will result in a growth of 190.34% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded KYMR stock several times over the past three months with 1 Buys and 0 Sells. In these transactions, 12,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 14 while that of sell transactions has risen to 52 over the past year. The total number of shares bought during that period was 254,519 while 1,762,829 shares were sold.
